Abstract
Epigenetic control is necessary for tissue homeostasis, which is preserved through the self-renewal and differentiation of somatic stem cells, as well as for development. Leukemia stem cells and self-renewing hematopoietic stem cells are both maintained by epigenetic regulators, according to mounting evidence. In hematologic malignancies, recent genome-wide comprehensive investigations have discovered mutations in genes that regulate epigenetic processes, including genes whose products change DNA and histones. Both cell-intrinsic and cell-extrinsic regulators, such as transcription factors, signal transduction pathways, and niche factors, affect hematopoietic stem cells. However, little is known about the process through which epigenetic regulators work in conjunction with these elements to maintain blood homeostasis. With an emphasis on the function of DNA-methylation modulators in hematopoietic cells and their offspring, we review current discoveries in the epigenetic control of hematopoiesis in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AML:
-
Acute myeloid leukemia
- DNMTi:
-
DNA-methyltransferase inhibitors
- HATs:
-
Histone acetyl transferases
- KG:
-
Ketoglutarate
- Len:
-
Lenalidomide
- MDS:
-
Myelodysplastic syndromes
- MPN:
-
Myeloproliferative neoplasms
- OS:
-
Overall survival
- PRC:
-
Polycomb repressive complexes
- TET:
-
Ten-Eleven-Translocation
References
Abdel-Wahab O, Mullally A, Hedvat C et al (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114(1):144–147. https://doi.org/10.1182/blood-2009-03-210039
Ashburner BP, Westerheide SD, Baldwin AS Jr (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21(20):7065–7077. https://doi.org/10.1128/MCB.21.20.7065-7077.2001
Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21(3):381–395. https://doi.org/10.1038/cr.2011.22
Barneda-Zahonero B, Parra M (2012) Histone deacetylases and cancer. Mol Oncol 6(6):579–589. https://doi.org/10.1016/j.molonc.2012.07.003
Bojang P Jr, Ramos KS (2014) The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev 40(1):153–169. https://doi.org/10.1016/j.ctrv.2013.05.009
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769–784. https://doi.org/10.1038/nrd2133
Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9(1):34. Published 2017 Apr 19:34. https://doi.org/10.1186/s13073-017-0424-2
Chung YR, Schatoff E, Abdel-Wahab O (2012) Epigenetic alterations in hematopoietic malignancies. Int J Hematol 96(4):413–427. https://doi.org/10.1007/s12185-012-1181-z
Corrales-Medina FF, Manton CA, Orlowski RZ, J. (2015) Chandra efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leuk Res 39(3):371–379
Cruz-Rodriguez, N., Combita, A.L., Zabaleta, J. (2018). Epigenetics in Hematological Malignancies. In: Dumitrescu, R., Verma, M. (eds) Cancer Epigenetics for Precision Medicine . Methods in Molecular Biology, vol 1856. Humana Press, New York, NY https://doi.org/10.1007/978-1-4939-8751-1_5
Deleu S, Lemaire M, Arts J et al (2009) Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 69(13):5307–5311. https://doi.org/10.1158/0008-5472.CAN-08-4472
Dimopoulos K, Gimsing P, Grønbæk K (2014) The role of epigenetics in the biology of multiple myeloma. Blood Cancer J 4(5):e207. Published 2014 May 2. https://doi.org/10.1038/bcj.2014.29
Dimopoulos K, Grønbaek K (2019) Epigenetic therapy in hematological cancers. APMIS 127(5):316–328. https://doi.org/10.1111/apm.12906
Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) [published correction appears in Blood. 2007 Jun 15;109(12):5086]. Blood 109(1):31–39. https://doi.org/10.1182/blood-2006-06-025999
Fong CY, Morison J, Dawson MA (2014) Epigenetics in the hematologic malignancies. Haematologica 99(12):1772–1783. https://doi.org/10.3324/haematol.2013.092007
Gao XN, Lin J, Ning QY et al (2013) A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS One 8(2):e55481. https://doi.org/10.1371/journal.pone.0055481
Greenblatt S, Nimer S (2014) Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia 28:1396–1406. https://doi.org/10.1038/leu.2014.94
Gruhn B, Naumann T, Gruner D et al (2013) The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Leuk Res 37(10):1200–1207. https://doi.org/10.1016/j.leukres.2013.07.016
Gupta M, Han J, Stenson M et al (2012) Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26:1356–1364. https://doi.org/10.1038/leu.2011.340
Hayakawa J, Kanda J, Akahoshi Y et al (2017) Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. Int J Hematol 105(5):578–586. https://doi.org/10.1007/s12185-017-2179-3
He YF, Li BZ, Li Z et al (2011) Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333(6047):1303–1307. https://doi.org/10.1126/science.1210944
Heo JN, Kim DY, Lim SG et al (2019) ER stress differentially affects pro-inflammatory changes induced by mitochondrial dysfunction in the human monocytic leukemia cell line, THP-1. Cell Biol Int 43(3):313–322. https://doi.org/10.1002/cbin.11103
Huntly BJ, Shigematsu H, Deguchi K et al (2004) MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6(6):587–596. https://doi.org/10.1016/j.ccr.2004.10.015
Inthal A, Zeitlhofer P, Zeginigg M et al (2012) CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 26:1797–1803. https://doi.org/10.1038/leu.2012.60
Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H (2015 Sep) Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16(9):1099–1110. https://doi.org/10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19. PMID: 26296954; PMCID: PMC5557041.
Ito S, D’Alessio AC, Taranova OV et al (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466(7310):1129–1133. https://doi.org/10.1038/nature09303
Ito S, Shen L, Dai Q et al (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333(6047):1300–1303. https://doi.org/10.1126/science.1210597
Itzykson R, Kosmider O, Cluzeau T et al (2011) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25(7):1147–1152. https://doi.org/10.1038/leu.2011.71
Kantarjian HM, Roboz GJ, Kropf PL et al (2017) Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol 18(10):1317–1326. https://doi.org/10.1016/S1470-2045(17)30576-4
Kleff S, Andrulis ED, Anderson CW, Sternglanz R (1995) Identification of a gene encoding a yeast histone H4 acetyltransferase. J Biol Chem 270(42):24674–24677. https://doi.org/10.1074/jbc.270.42.24674
Kurdistani SK, Grunstein M (2003) Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 4(4):276–284. https://doi.org/10.1038/nrm1075
Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M (2008) Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 49(7):1329–1336. https://doi.org/10.1080/10428190802108870
Langemeijer SM, Kuiper RP, Berends M et al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41(7):838–842. https://doi.org/10.1038/ng.391
Lavau C, Du C, Thirman M, Zeleznik-Le N (2000) Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 19(17):4655–4664. https://doi.org/10.1093/emboj/19.17.4655
Liang P, Song F, Ghosh S et al (2011) Genome-wide survey reveals dynamic widespread tissue-specific changes in DNA methylation during development. BMC Genomics 12(1):231. Published 2011 May 11. https://doi.org/10.1186/1471-2164-12-231
Luan C, Yang Z, Chen B (2015) The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy. Onco Targets Ther 8:2903–2914. https://doi.org/10.2147/OTT.S92470. PMID: 26508875; PMCID: PMC4610789
Malinowska-Ozdowy K, Frech C, Schönegger A et al (2015) KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia. Leukemia 29(8):1656–1667. https://doi.org/10.1038/leu.2015.107
Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10):1247–1252. https://doi.org/10.1634/theoncologist.12-10-1247
Mullighan CG, Zhang J, Kasper LH et al (2011) CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471(7337):235–239. https://doi.org/10.1038/nature09727
Nebbioso A, Carafa V, Conte M et al (2017) C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer. Clin Cancer Res 23(10):2542–2555. https://doi.org/10.1158/1078-0432.CCR-15-2388
Nemes K, Csóka M, Nagy N et al (2015) Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia. Pathol Oncol Res 21(3):597–604. https://doi.org/10.1007/s12253-014-9861-z
New M, Olzscha H, La Thangue NB (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 6(6):637–656. https://doi.org/10.1016/j.molonc.2012.09.003
Ohyashiki JH, Umezu T, Kobayashi C et al (2010) Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes 3:347. https://doi.org/10.1186/1756-0500-3-347
Olsen EA, Kim YH, Kuzel TM et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25(21):3109–3115. https://doi.org/10.1200/JCO.2006.10.2434
Pan D, Rampal R, Mascarenhas J (2020) Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. Blood Adv. 4(5):970–982. https://doi.org/10.1182/bloodadvances.2019001245. Erratum in: Blood Adv. 2020 Apr 14;4(7):1220. PMID: 32150613; PMCID: PMC7065485
Pasqualucci L, Dominguez-Sola D, Chiarenza A et al (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471(7337):189–195. https://doi.org/10.1038/nature09730
Piekarz RL, Frye R, Turner M et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27(32):5410–5417. https://doi.org/10.1200/JCO.2008.21.6150
Piletič K, Kunej T (2016) MicroRNA epigenetic signatures in human disease. Arch Toxicol 90(10):2405–2419. https://doi.org/10.1007/s00204-016-1815-7
Richard LP, Robert WR, Zhan Z et al (2004) T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103(12):4636–4643
San-Miguel JF, Hungria VT, Yoon SS et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial [published correction appears in Lancet Oncol. 2015 Jan;16(1):e6]. Lancet Oncol 15(11):1195–1206. https://doi.org/10.1016/S1470-2045(14)70440-1
Santo L, Hideshima T, Kung AL et al (2012) Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119(11):2579–2589. https://doi.org/10.1182/blood-2011-10-387365
Schotte D, De Menezes RX, Akbari Moqadam F et al (2011) MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia [published correction appears in Haematologica. 2011 Aug;96(8):1240]. Haematologica 96(5):703–711. https://doi.org/10.3324/haematol.2010.026138
Schotte D, Pieters R, Den Boer ML (2012) MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 26(1):1–12. https://doi.org/10.1038/leu.2011.151
Shahbazian MD, Grunstein M (2007) Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76(1):75–100
Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W (2014) The ten-eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 28(3):485–496. https://doi.org/10.1038/leu.2013.337
Srivastava P, Paluch BE, Matsuzaki J et al (2014) Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res 38:1332–1341
Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T (2016) Epigenetics in cancer: a hematological perspective. PLoS Genet 12(10):e1006193. https://doi.org/10.1371/journal.pgen.1006193. PMID: 27723796; PMCID: PMC5065123
Tahiliani M, Koh KP, Shen Y et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929):930–935. https://doi.org/10.1126/science.1170116
Van den Hove DL, Kompotis K, Lardenoije R et al (2014) Epigenetically regulated microRNAs in Alzheimer’s disease. Neurobiol Aging 35(4):731–745. https://doi.org/10.1016/j.neurobiolaging.2013.10.082
Ventura A, Young AG, Winslow MM et al (2008) Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132(5):875–886. https://doi.org/10.1016/j.cell.2008.02.019
Wang L, Gural A, Sun XJ et al (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333(6043):765–769. https://doi.org/10.1126/science.1201662
Wang Y, Li Z, He C et al (2010) MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis 44(3):191–197. https://doi.org/10.1016/j.bcmd.2009.12.010
Whittaker SJ, Demierre MF, Kim EJ et al (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28(29):4485–4491. https://doi.org/10.1200/JCO.2010.28.9066
Wouters BJ, Delwel R (2016 Jan 7) Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood 127(1):42–52. https://doi.org/10.1182/blood-2015-07-604512. Epub 2015 Dec 10. PMID: 26660432.
Wu H, Zhang Y (2011) Tet1 and 5-hydroxymethylation: a genome-wide view in mouse embryonic stem cells. Cell Cycle 10(15):2428–2436. https://doi.org/10.4161/cc.10.15.16930
Conflict of Interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
This article does not contain any studies involving human participants performed by any of the authors.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Atli, E.I. (2023). Epigenetic Alterations in Hematologic Malignancies. In: Kalkan, R. (eds) Cancer Epigenetics. Epigenetics and Human Health, vol 11. Springer, Cham. https://doi.org/10.1007/978-3-031-42365-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-031-42365-9_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-42364-2
Online ISBN: 978-3-031-42365-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)